We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Longeveron Inc (LGVN) USD0.0001 A

Sell:$1.15 Buy:$1.17 Change: $0.045 (3.64%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
Change: $0.045 (3.64%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
Change: $0.045 (3.64%)
Market closed |  Prices as at close on 21 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Contact details

1951 NW 7th Ave, Ste 520
United States
+1 (305) 3027158

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$7.84 million
Shares in issue:
6.35 million
United States
US dollar

Key personnel

  • Joshua Hare
    Chairman of the Board, Co-Founder, Chief Science Officer
  • Wa'el Hashad
    Chief Executive Officer, Director
  • Donald Soffer
    Co-Founder, Director
  • Lisa Locklear
    Chief Financial Officer, Executive Vice President
  • Paul Lehr
    General Counsel, Corporate Secretary, International Executive Director
  • Nataliya Agafonova
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.